Search

  6. ProQR Announces Second Quarter 2023 Operating and Financial Results

    Press release

    Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline €129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026

  7. Presentations & Publications

    Página

    … at medical conferences. Axiomer technology Axiomer RNA editing technology Download link Oligonucleotide Based …

    Scientist working in ProQR's laboratories

  8. Partnerships

    Página

    ProQR has collaborations with important names in the industry including Eli Lilly and Company. Read more about our partnerships.

    A ProQRian working on a cell culture in the laboratory

  9. Careers

    Página

    At our offices in Leiden we are advancing our proprietary Axiomer RNA-editing platform technology. Our ProQRians, representing over 30 nationalities, are passionate and driven to change the lives of patients and their loved ones.

    ProQRians in a meeting

  10. About ProQR Therapeutics

    Página

    An innovative biotech company advancing our proprietary Axiomer RNA-editing platform technology.

    Female scientist working in ProQR's laboratories